|
|
Vaccine Comparison
|
Salmonella Typhimurium gyrA/cpxA/rpoB mutant vaccine |
Salmonella Typhimurium ompD/nmpC mutant vaccine |
| Vaccine Information |
Vaccine Information |
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Pigs
- cpxA
gene engineering:
- Type: Gene mutation
- Description: This gyrA/cpxA/rpoB mutant is from Salmonella Typhimurium (Roesler et al., 2004).
- Detailed Gene Information: Click Here.
- gyrA
gene engineering:
- Type: Gene mutation
- Description: This gyrA/cpxA/rpoB mutant is from Salmonella Typhimurium (Roesler et al., 2004).
- Detailed Gene Information: Click Here.
- rpoB
gene engineering:
- Type: Gene mutation
- Description: This gyrA/cpxA/rpoB mutant is from Salmonella Typhimurium (Roesler et al., 2004).
- Detailed Gene Information: Click Here.
- Immunization Route: Oral immunization
|
- Vaccine Ontology ID: VO_0002900
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Pig
- NmpC
gene engineering:
- Type: Gene mutation
- Description: This ompD/nmpC mutant is from Salmonella Typhimurium (Selke et al., 2007).
- Detailed Gene Information: Click Here.
- Immunization Route: Oral immunization
|
| Host Response |
Host Response |
|
Pig Response
- Persistence: A gyrA/cpxA/rpoB mutant was attenuated in pigs (Roesler et al., 2004).
- Efficacy: A gyrA/cpxA/rpoB mutant protected pigs against challenge with wild type Salmonella Typhimurium (Roesler et al., 2004).
- Host IgM response
- Description: A significant discrimination between vaccinated and non-vaccinated pigs was observed when IgM was measured after challenge, but here, the non-immunized animals had an elevated humoral antibody response after challenge with wild type Salmonella. The first significant difference was seen on day 35 after vaccination (Roesler et al., 2004).
- Detailed Gene Information: Click Here.
|
Pig Response
- Persistence: An ompD/nmpc mutant is attenuated in pigs (Selke et al., 2007).
- Efficacy: In a pig infection experiment including two oral immunizations with SalmoporcDeltaompD (OmpD, nmpC) and challenge with a multiresistant S. enterica serovar Typhimurium DT104 clinical isolate, we confirmed the protective efficacy of SalmoporcDeltaompD (Selke et al., 2007).
|
| References |
References |
Roesler et al., 2004: Roesler U, Marg H, Schröder I, Mauer S, Arnold T, Lehmann J, Truyen U, Hensel A. Oral vaccination of pigs with an invasive gyrA-cpxA-rpoB Salmonella Typhimurium mutant. Vaccine. 2004; 23(5); 595-603. [PubMed: 15542179].
|
Selke et al., 2007: Selke M, Meens J, Springer S, Frank R, Gerlach GF. Immunization of pigs to prevent disease in humans: construction and protective efficacy of a Salmonella enterica serovar Typhimurium live negative-marker vaccine. Infection and immunity. 2007; 75(5); 2476-2483. [PubMed: 17296750].
|
|
